Is Exelixis, Inc. (EXEL) a Buy? The Stock Rises Again

April 17, 2018 - By Marguerite Chambers

Exelixis, Inc. (NASDAQ:EXEL) Logo

Investors sentiment increased to 1.57 in Q4 2017. Its up 0.34, from 1.23 in 2017Q3. It improved, as 26 investors sold Exelixis, Inc. shares while 66 reduced holdings. 59 funds opened positions while 85 raised stakes. 232.85 million shares or 1.85% less from 237.25 million shares in 2017Q3 were reported.
Point72 Asia (Hong Kong) reported 503 shares. Klingenstein Fields Com Limited Liability Company invested in 7,000 shares. Quantitative Ltd Company holds 0.02% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 53,000 shares. Piermont Mngmt Inc has 14,830 shares. 1832 Asset L P holds 1.87M shares or 0.18% of its portfolio. Trexquant Investment L P has invested 0.23% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Stephens Inv Management Grp Limited Liability Com reported 0.32% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Kingdon Mngmt Limited Co reported 0.48% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Pictet Asset Ltd owns 1.91M shares for 0.15% of their portfolio. Fmr Limited Liability Corp stated it has 0.13% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Grp Inc One Trading Ltd Partnership accumulated 0.1% or 459,959 shares. 2.69 million are held by Jpmorgan Chase And. Moreover, Rhenman Ptnrs Asset Mngmt Ab has 3.11% invested in Exelixis, Inc. (NASDAQ:EXEL). Amp Cap holds 9,800 shares. Css Limited Liability Corporation Il holds 265,762 shares or 0.4% of its portfolio.

Since January 8, 2018, it had 0 buys, and 9 selling transactions for $6.02 million activity. Another trade for 15,000 shares valued at $370,950 was sold by MARCHESI VINCENT T. 15,000 shares were sold by POSTE GEORGE, worth $393,900 on Wednesday, February 28. 15,000 shares were sold by COHEN CHARLES, worth $363,450 on Monday, March 5. PAPADOPOULOS STELIOS had sold 15,000 shares worth $360,750 on Friday, March 2. Another trade for 11,000 shares valued at $262,680 was sold by FELDBAUM CARL B. $1.87 million worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by MORRISSEY MICHAEL on Wednesday, April 11.

The stock of Exelixis, Inc. (NASDAQ:EXEL) is a huge mover today! The stock increased 6.23% or $1.27 during the last trading session, reaching $21.67. About 2.54M shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 5.01% since April 17, 2017 and is uptrending. It has underperformed by 6.54% the S&P500.
The move comes after 8 months positive chart setup for the $6.43 billion company. It was reported on Apr, 17 by Barchart.com. We have $22.32 PT which if reached, will make NASDAQ:EXEL worth $192.87 million more.

Analysts await Exelixis, Inc. (NASDAQ:EXEL) to report earnings on May, 7. They expect $0.13 earnings per share, up 160.00 % or $0.08 from last year’s $0.05 per share. EXEL’s profit will be $38.57M for 41.67 P/E if the $0.13 EPS becomes a reality. After $0.12 actual earnings per share reported by Exelixis, Inc. for the previous quarter, Wall Street now forecasts 8.33 % EPS growth.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 5 analysts covering Exelixis (NASDAQ:EXEL), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Exelixis had 7 analyst reports since December 19, 2017 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, February 27 report. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Outperform” rating given on Tuesday, February 27 by Oppenheimer. The rating was maintained by SunTrust with “Buy” on Tuesday, December 19. The rating was maintained by RBC Capital Markets on Tuesday, January 16 with “Buy”. The firm earned “Buy” rating on Thursday, January 4 by Piper Jaffray. As per Monday, January 22, the company rating was maintained by SunTrust. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, February 27.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $6.43 billion. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 43.96 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.